Scout Bio

Scout Bio is revolutionizing veterinary medicine with its one-time therapies for chronic pet health conditions. The company's mission is to leverage the genetic revolution in human medicine to shape the future of veterinary medicine. By combining expertise in animal health and gene therapy technology, Scout has developed a platform for one-time therapies addressing unmet medical needs in pet medicine. Scout Bio's groundbreaking approach has garnered support from leading life sciences investors, and the company has a strategic R&D collaboration with the esteemed Gene Therapy Program at the University of Pennsylvania. Founded in 2016, Scout's focus on biotechnology and health care positions it at the forefront of innovation in the industry. The most recent Series B investment of $33.00M received on 19 October 2021 signifies the confidence of investors in Scout Bio's potential. Notable investors in this round include Correlation Ventures, Greenspring Associates, Frazier Healthcare Partners, OrbiMed, RiverVest, Adage Capital Management, and Digitalis Ventures. With its first therapy aimed at addressing anemia associated with chronic kidney disease in cats, Scout Bio is actively enrolling cats in a groundbreaking study across the U.S. The success of this therapy, involving a single injection and 70 days of monitoring, has the potential to relieve a cat's anemia for life, marking a significant advancement in veterinary medicine. For more information, interested individuals and clinics can visit www.scoutbio.co/catEPOstudy. In conclusion, Scout Bio's innovative approach, strong investor backing, and potential to transform veterinary medicine positions it as a compelling player in the biotechnology and healthcare industries.